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INTRODUCTION 56
Autism spectrum disorder (ASD) affects 1-2% of the population worldwide(1). The 57 majority of individuals diagnosed with ASD, including those without intellectual disability (ID), 58 feature prominent functional impairment and require substantial support(2-4). Evidence-59 based treatment options are particularly lacking for 13-30 year-olds with ASD where no 60 intervention has been shown to improve long-term outcomes(5). The heterogeneity that is 61 inherent to ASD and the absence of consistent biological markers are key challenges for 62 treatment innovation(6). 63 Executive functions (EF) are high-order cognitive functions necessary for shifting 64 flexibly from one focus to another (set-shifting), controlling/regulating behavior (response 65 inhibition), and maintaining and manipulating information over a short period of time 66 (working memory) (7) . A recent meta-analysis characterized the presence and stability 67 across development of impaired EF performance (with a moderate effect size) in ASD 68 versus age and IQ-matched control groups across multiple domains (e.g., planning, working 69 memory, mental flexibility)(8). As EF performance is a strong predictor of adaptive 70 (everyday) functioning and mental health in ASD(9, 10), interventions that target EF deficits 71 could have a clinically meaningful impact on functional outcomes. 72 Repetitive transcranial magnetic stimulation (rTMS) involves stimulation of the 73 superficial cortex by a train of magnetic field pulses at typical frequencies between 1 to 74 20Hz(11). Based on favorable safety and efficacy, high frequency rTMS to left dorsolateral 75 prefrontal cortex (DLPFC) is an approved treatment for depression (12) . Improvement on 76 secondary neuropsychological outcomes in efficacy studies for depression has sparked 77 interest in developing TMS interventions for cognition (13) . A meta-analysis examining 78 studies that included adults with depression, schizophrenia, Alzheimer's dementia or 79 unimpaired controls, indicated that protocols using repeated sessions of high frequency 80 rTMS to DLPFC were most promising for improvement of EF outcomes (13). Preliminary 81 RCTs (n=17-36) exploring rTMS effects on specific domains have shown improved verbal 82 memory recall(14), facial affect recognition(15) and working memory(16) in participants with 83 chronic schizophrenia following active rTMS to DLPFC versus sham stimulation with large 84 effect sizes reported (15, 16) . 85 Several smaller studies provide preliminary support for the feasibility and 86 acceptability of rTMS as an intervention for individuals with ASD(17) . Two open-label 87 studies (n=40 and 54, respectively) showed improved performance on a selective attention 88 task following 12-18 weeks of once-weekly, 1Hz rTMS delivered at 90% resting motor 89 threshold (RMT), stimulating left-only or bilateral DLPFC in 9-21 year-olds with ASD without 90 ID, compared to a waitlist control group (18, 19) . Only one controlled study of daily rTMS 91 sessions has been published in ASD (20) . That RCT showed a reduction in self-reported 92 social relating symptoms measured on the Ritvo Autism-Asperger Diagnostic Scale in 93 adults with ASD that received two weeks of weekday 5Hz rTMS at 90% RMT to bilateral 94 dorsomedial prefrontal cortex versus sham stimulation (n=28). No study that we are aware 95 of has examined whether rTMS can enhance EF in persons with ASD(20) . 96 The fronto-parietal network (comprised of DLPFC, and parietal cortex along the 97 intraparietal sulcus) is hypothesized to support engagement and flexible integration of 98 distributed brain networks, supporting high-order cognitive ability, including EF(21). A 99 number of neuroimaging studies have found evidence of altered functional MRI-measured 100 DLPFC activation or altered distributed frontoparietal network connectivity during spatial 101 working memory (SWM) performance in children (22) or adults with ASD versus controls(23-Participants were initially screened over telephone. An interest was change in CANTAB SWM total errors (pre-to-post rTMS score differences). Figure 1 ). Ninety-five percent of eligible participants were enrolled. Two participants 265 allocated to active treatment (5%) dropped out after 1-2 rTMS sessions. Thirty-eight 266 participants remained in the trial until treatment end (95% retention). See Table 1 and   267   Supplementary Table 1 for participant demographic and clinical characteristics at baseline. 268 In the final sample, a larger number of females were enrolled in the study than expected 269 based on the updated prevalence literature (i.e., male-to-female ratio in our ASD 270 sample=2.3:1 versus 3.3:1 expected ratio)(43). See Supplementary Table 2 for p=0.3, effect size=0.28, 95%CI=-2.7-7.7) from baseline to endpoint are detailed in Table 3 . 304 A significant main effect of time was found for SWM total errors (F 2,67 =5.17, p=0.008) and 305 BRIEF-MCI score (F 2,68 =28.4, p<0.0001), indicating that mean group performance improved 306 across participants over the trial period. Main effects for baseline SWM total errors 307 (F 2,67 =283.2, p<0.0001) and BRIEF-MCI scores (F 2,68 =105, p<0.0001) were also found, 308 indicating that baseline score predicted outcome score. No clear pattern of differential Cohen's f 2 =0.05) was also found, driven by greater reductions in BRIEF-MCI-measured 319 deficits and SWM total errors in females following active versus sham treatment (see Fig. 5 ). The current pilot trial is the first to examine the feasibility, acceptability and clinical 327 effects of rTMS for EF deficits in an autism sample. Our pilot study demonstrated good 328 feasibility and acceptability of a 20-session course of 20Hz rTMS to DLPFC applied to youth 329 and young adults with ASD. We did not find preliminary evidence for efficacy for active vs. 
